York, NY), the first azalide antibiotic, has been approved for the single-dose treatment of nongonococcal urethritis and cervicitis due to Chlamydia trachomatis. In addition, azithromycin is useful in a 5-day regimen for the treatment of indicated respiratory-tract and skin and skin-structure infections (Table 1 ) (unpublished data, Pfizer, Inc., 1996) . C. trachomatis is the most common sexually transmitted pathogen in the United States. An obligate intracellular parasite, C. trachomatis is the leading cause of nongonococcal urethritis and epididymitis in men under 35 years of age. In women, it causes mucopurulent cervicitis, urethral syndrome, and pelvic inflammatory disease (PID).
The health-care costs of C. trachomatis infections are substantial. In 1990, the direct and indirect costs incurred with PID and PID-associated ectopic pregnancy and infertility--medical problems frequently arising from untreated, uncomplicated chlamydial infections--were estimated to be $4.2 billion.
The treatment of genital chlamydial infections has been difficult. Tetracycline or doxycycline administered orally for h after a 500-rag intravenous (IV) dose] is more than 10-fold that of other available macrolides. 7, 12 The concentration of azithromycin in most tissues exceeds that in serum by 10-to 100-fold. 12 The projected tissue levels in the prostate or uterus following a single 1-g dose remain well above the minimum inhibitory concentration for 90% (MICg0) of C. trachomatis isolates for as long as 10 days (Fig.  1) 
